AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02791750 — intervention group
Intervention type: OTHER
Intervention: questionnary of quality of life
Study NCT06631560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA testing
Description: Diagnostic testing was performed by testing all serum samples using the HEV ELISA Wantai and Euroimmun kit.
Study NCT01383395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin/cilostazol
Study NCT04319562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle-embedding therapy
Description: First group is comprised of Xinshu (BL15), Ganshu (BL18), Juque (CV14) bilaterally, and Xin and Gan of auricular point on the left ear. Second group includes Shentang (BL44), Hunmen (BL47), Jiuwei (RN15) bilaterally, and Xin and Gan of auricular point on the right side.~After skin cleansing with a 75% alcohol swab, intradermal thumbtack needle will be quickly inserted into the skin and embedded at acupoints mentioned above bilaterally. The needles will remain in the acupoints for 3 days and they will be removed by the therapists at next visit. This also can ensure better implementation of the blind method.Participants are required to receive this treatment twice a week. The specification of the needle used in the back shu point is φ9mm 0.20×1.5mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan), that in the auricular point is φ9mm 0.20×0.6mm (Seirin® PYONEX; Seirin Corporation, Shizuoka, Japan).
Study NCT04319562 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shame needle-embedding therapy
Description: The acupoint selection in this group is the same as in the needle-embedding therapy group, except that the shame intradermal needles will be used. After skin cleansing with a 75% alcohol swab, the shame intradermal needles，instead of insert into the skin, it can only stick on the surface of the skin. It also will be removed by the therapists after 3 days. This takes place twice a week. The specification of the shame needle is the same as above.
Study NCT04220489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intraoperative ketamine and post operative 48 hour ketamine infusion with a standardized general anesthesia protocol.
Study NCT04220489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure)
Study NCT04043338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC130-A10H
Description: XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
Study NCT04043338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied as matching capsules or tablets
Study NCT02392039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
Study NCT02392039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
Study NCT01480752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
Study NCT01480752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: no injection
Description: inject nothing after inferior alveolar injection and before root canal therapy
Study NCT02392039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
Study NCT02392039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
Study NCT02876055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single shot interscalene nerve block
Description: Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
Study NCT02876055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous interscalene nerve block
Description: Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
Study NCT02876055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Infiltration Analgesia (LIA)
Description: Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
Study NCT01920620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient weight loss counseling
Description: Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
Study NCT01920620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and troubleshooting via phone
Description: All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
Study NCT03736538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
Study NCT03736538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gas
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Study NCT02391844 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Oxycodone with Acetaminophen Extended Release
Study NCT02861027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPTHA
Description: The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
Study NCT02861027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPTHA
Description: The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
Study NCT02861027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FES and PPTHA
Description: The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
Study NCT01606228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
Study NCT02293473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO Rapid
Description: LiDCO Rapid haemodynamic monitor
Study NCT02293473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS-Bispectral Index Monitor
Description: Depth of anaesthesia
Study NCT02293473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOS-Cerebral Oxygenation Monitor
Description: regional brain tissue oxygenation
Study NCT02293473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Using standard of care
Study NCT00373425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg tablet
Study NCT00373425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT01826916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-88 (ecallantide)
Description: solution for injection 10 mg/mL
Study NCT02276768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001 375 mg TID
Description: GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
Study NCT02276768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001 500 mg TID
Description: GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
Study NCT02276768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)
Description: GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
Study NCT02276768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GIC-1002 460 mg (equimolar to GIC-1001 500 mg)
Description: GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
Study NCT02276768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical and matching active drugs GIC-1001 and GIC-1001
Study NCT01563458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: 120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
Study NCT01563458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: 60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
Study NCT01563458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
Study NCT00471991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SH T04769G
Description: The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
Study NCT00471991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol / dienogest (SH D00659 AF)
Description: The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
Study NCT01293266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
Study NCT00949728 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conjunctival autograft using fibrin glue
Description: Conjunctival autograft using fibrin glue in pterygium surgery
Study NCT02601768 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter closure of ASD II
Description: Transcatheter closure of ASD II performed in our center.
Study NCT03900117 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: split-course radiotherapy
Description: Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
Study NCT03900117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
Study NCT01731522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EF condition
Study NCT02269631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Legume diet group
Description: about 1 1/2 cups of legumes included in lunch and dinner meals
Study NCT02269631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet group
Description: no legumes in lunch or dinner meals
Study NCT02269631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartpill
Description: to assess how long food takes to pass through the digestive system
Study NCT02269631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartpill
Description: to assess how long food takes to pass through the digestive system
Study NCT02269631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: legumes
Description: about 1 1/2 cups of legumes included in lunch and dinner meals
Study NCT01253395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Daily supervised strength training.
Study NCT01253395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Daily supervised aerobic exercise.
Study NCT02610270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 Gums
Description: 760 mg DHA
Study NCT02610270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 Gums
Description: 1140 mg DHA
Study NCT04664816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-3PUFAs Treatment
Description: Omega-3 plus (1200 mg) orally, twice a day for at least 12 months.
Study NCT04664816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Placebo orally, twice a day for at least 12 months.
Study NCT02931292 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained.
Study NCT00359619 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CervarixTM
Description: Subjects were administered three doses of HPV vaccine
Study NCT00359619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV investigational vaccine GSK568893A, different formulations
Description: Subjects were administered three doses of HPV investigational vaccine
Study NCT00693225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole/sodium bicarbonate
Description: Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
Study NCT00693225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/sodium bicarbonate
Description: Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
Study NCT03893916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEG - EEG HR
Description: MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools.
Study NCT03042468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: 177Lu-PSMA-617 \[50mCi (1.85GBq) - 300mCi (11.1GBq)\] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
Study NCT03042468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-HBED-CC
Description: 68Ga-PSMA-HBED-CC \[5 ±2mCi or 185 ±74MBq\] intravenous during screening and at 12 weeks with standard imaging
Study NCT00587288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reslizumab
Study NCT00587288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00876044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (AVE0005)
Description: Intravenous route
Study NCT00876044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous route
Study NCT01414231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
Study NCT02452294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
Study NCT03151564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Scan - 50% Dose Reduction
Description: Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.